ÂÜÀòÂÒÂ×

Michael Houston, Ph.D. brings over 25 years of experience as a leader in the biotech and pharmaceutical industries to Cytonus. Dr. Houston worked as the CSO of TriLink where he led teams developing new mRNA capping technologies as well as optimizing processes for making mRNA therapeutics and vaccines. Prior to TriLink, he was the CSO at PhaseRx, where he developed mRNA-based therapeutics. Dr. Houston served as Vice President of Chemistry and Formulations for Marina Biotech, where he led a team in the development of siRNA-based therapies and LNP-based delivery systems. He has considerable experience in peptide-based therapeutics, as demonstrated in his role as VP of Preclinical Chemistry and CMC at Ascent Therapeutics. Dr. Houston also served as Senior Director of Chemistry and Formulations at Nastech Pharmaceutics. He received a Ph.D. in bio-organic chemistry and a B.Sc. with honors in chemistry from the University of Waterloo in Ontario, Canada.